For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
Home  /  Database  /  Bromantane
Cognitiveearly_human

Bromantane

Ladasten
Cognitive
ASK VERA ABOUT THIS ↗BROWSE THE CATALOG ↗
Category
Cognitive
Evidence grade
C
PubMed records
62
Female-tagged
16
Sex-analysis
1
CAS
—
C
Evidence grade C, Early human data only (Phase 1 / small-n) across 62 indexed studies. How grades work →
Female evidence: Extrapolated
Bromantane: of 62 PubMed records, 16 are tagged as including female subjects and 1 carry a sex-analysis tag.Counts reflect PubMed records as of 2026-07-21. “Female” uses the Female MeSH filter and “sex-analysis” the Sex Factors MeSH filter, automated proxies pending manual study-level review. Methodology →

Overview

Bromantane is an adamantane-derived compound developed in Russia and studied as an actoprotector, a class of agents investigated for their combined influence on physical performance and stress adaptation. Its lipophilic adamantane core gives it an unusual pharmacological profile compared with more conventional stimulant research materials.

In preclinical models, bromantane has been studied for its association with dopaminergic signaling and biosynthesis, and for stress-response and fatigue-adaptation pathways. Researchers examining actoprotective and adaptogenic mechanisms have used it as a research material in behavioral and neurochemical models.

For a cognitive and neurological catalog, bromantane is distinctive as a bridge between stimulant-like and adaptogen-like mechanisms rather than fitting neatly into either. Whether these mechanisms translate the same way across female physiology remains an open research question; our evidence review tracks how many of the underlying studies included women.

Summary

Bromantane is an 'actoprotector' developed in Russia and approved there (as Ladasten) for asthenic conditions, combining mild stimulant and anxiolytic effects. Its clinical evidence is largely from the Russian literature and is not analyzed for female-specific outcomes.

Evidence in women

Menstrual cycle
Unstudied
No study examined bromantane across the menstrual cycle.
Pregnancy & lactation
Unstudied
No pregnancy or lactation safety data exist.
Hormonal interactions
Unstudied
No controlled data on reproductive- or thyroid-hormone interactions.
Perimenopause & menopause
Unstudied
No perimenopausal or menopausal data.
Sex differences
Unstudied
Russian clinical reports included women but were not analyzed by sex.

Mechanism

Proposed to enhance dopamine synthesis and modulate stress-resistance pathways, producing combined stimulating and calming effects.

Reported dosing & routes

◐

We don't give dosing or medical advice. The figures below describe what was used in published research, not a recommendation. Decide with your clinician.

Reported range (literature)Oral doses (e.g., ~50–100 mg/day) are described in the Russian literature; not approved outside those markets.
Routesoral
Female-specific dosingNot established

Contraindications: insufficient independently-verified data to characterize

Side effects

Reported in the research literature. Sex-specific incidence has not been separately analysed in the available records.

insomnia (if taken late)insufficient rigorous safety data to fully characterize

Bromantane reconstitution calculator

Enter this vial's amount, the bacteriostatic water you add, and a target amount to get the concentration and the U-100 syringe units to draw. Handling arithmetic for research use, not a dose recommendation.

Reconstitution

1
2
3

Draw for Bromantane

5
units on a U-100 insulin syringe
020406080100
U-100 insulin syringe — 1 mL = 100 units
That's 0.05 mL drawn to the 5-unit mark.
Concentration5 mg/mL (5,000 mcg/mL)
Volume to draw0.05 mL
Doses per vial40

Reference chart at 5 mg/mL

Target amountVolume (mL)U-100 units
100 mcg0.02 mL2
250 mcg0.05 mL5
500 mcg0.1 mL10
750 mcg0.15 mL15
1000 mcg0.2 mL20

Research-use arithmetic only. This tool converts a vial amount, diluent volume, and a target amount into a concentration and syringe draw for laboratory handling. It is not dosing guidance, a recommendation, or a claim of safety or efficacy, and it does not account for overfill, dead space, or peptide purity. Nothing here is medical advice. “U-100” means 100 units = 1 mL; confirm your syringe graduation before measuring. See the reconstitution & storage handbook for handling detail.

Frequently asked questions

Answers drawn only from Bromantane's research facts and, where reviewed, its sex-disaggregated evidence. Nothing here is medical advice, dosing, or a claim of safety or efficacy.

What is Bromantane?

Bromantane, also known as Ladasten, is a research compound in our cognitive category. Bromantane is an 'actoprotector' developed in Russia and approved there (as Ladasten) for asthenic conditions, combining mild stimulant and anxiolytic effects.

Is Bromantane studied in women?

Bromantane: of 62 PubMed records, 16 are tagged as including female subjects and 1 carry a sex-analysis tag. We grade this extrapolated: women appear in the record, but no study is tagged for a sex-specific analysis, so female-relevant conclusions are inferred from mixed or male data rather than measured in women. See our methodology.

Has Bromantane been studied during pregnancy or breastfeeding?

Unstudied. No pregnancy or lactation safety data exist. This is not a safety clearance or a recommendation. Vera, our research chat, deliberately hard-stops on pregnancy, breastfeeding, and trying-to-conceive questions rather than answer them.

What evidence grade does Bromantane have, and why?

Bromantane carries evidence grade C. Early human data only (Phase 1 / small-n) across 62 indexed studies.. Grades are derived from the research record, never hand-assigned; see how grades work.

Is there a female-specific dose for Bromantane?

No. A female-specific dose for Bromantane is not established, and this site does not provide dosing or medical advice. Any figures we show describe what published research used, not a recommendation. Decide anything about use with a qualified clinician.

How is Bromantane administered in research?

In the published literature, Bromantane is administered via oral. Reported dose ranges on the Dosing tab describe what studies used for laboratory research, not a protocol for people. We don't provide dosing.

What side effects have been reported for Bromantane?

Effects reported in the research literature include insomnia (if taken late), insufficient rigorous safety data to fully characterize. Sex-specific incidence has not been separately analysed in the available records, so these are not broken out for women.

How should Bromantane be stored and handled?

Bromantane sold for research is supplied as a lyophilized (freeze-dried) powder. Lyophilized peptides are generally kept cold and dry, at roughly -20°C for longer-term storage and 2-8°C short-term, protected from light. Once reconstituted they are typically refrigerated and used within a short window, avoiding repeated freeze-thaw cycles. This is general laboratory handling for research use only, not a directive for human use. Always follow the handling and purity details on the product's Certificate of Analysis.

Where can I buy Bromantane for research?

Bromantane is not currently listed by our research-use partner, Aurevena Research, but their catalog carries related compounds. Code research15 applies 15% off. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.

Browse the Aurevena catalog
Research-use supplier: Bromantane isn't currently listed by our research-use vendor. Their catalog carries related compounds. Code research15 for 15% off, applied automatically at checkout. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.
Browse the catalog →

Citations (PMID)

24009833 · 34445021

Related peptides

Arginine VasopressinA
Arginine Vasopressin: of 12,241 PubMed records, 4,072 are tagged as including female subjects and 100 carry a sex-analysis tag.
CerebrolysinB
Cerebrolysin: of 629 PubMed records, 172 are tagged as including female subjects and 0 carry a sex-analysis tag.
DavunetideB
Davunetide: of 102 PubMed records, 24 are tagged as including female subjects and 4 carry a sex-analysis tag.
DihexaD
Dihexa: of 17 PubMed records, 0 are tagged as including female subjects and 0 carry a sex-analysis tag.

Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe.